- JATT mastermind launches latest biotech-focused SPAC via $60M IPOJust two months after Someit Sidhu, M.D., succeeded in pairing off his second special purpose acquisition company (SPAC) with Talawar Therapeutics, the biotech entrepreneur is back at it again.Fierce Biotech · 5h ago↗ source
- Spyre’s rheumatoid arthritis plan toppled by subpar TL1A dataPhase 2 data on Spyre Therapeutics’ anti-TL1A antibody SPY072 in rheumatoid arthritis have fallen short of expectations, prompting the biotech to deprioritize monotherapy development in the indicat…Fierce Biotech · 10h ago↗ source
- J&J’s Imaavy gains first-in-class label for warm autoimmune hemolytic anemiaJ&J announced that its monoclonal antibody Imaavy has received a label expansion in the United States. The expanded indication makes Imaavy the first therapy approved specifically for warm autoimm…